Indivior Pharmaceuticals (INDV) Non Operating Interest Expenses (2024 - 2026)

Indivior Pharmaceuticals has reported Non Operating Interest Expenses for 3 years, with the latest figure at $2.0 million in Q2 2026.

• On a quarterly basis, Non Operating Interest Expenses fell 86.67% year-over-year to $2.0 million in Q2 2026; TTM through Jun 2026 was $27.0 million, a 47.06% decrease from a year earlier, with the FY2025 full-year figure at $45.0 million, up 9.76% from the prior year.
• Non Operating Interest Expenses was $2.0 million for Q2 2026 at Indivior Pharmaceuticals, down from $7.0 million in the prior quarter.
• The five-year high for Non Operating Interest Expenses was $15.0 million in Q2 2025, with the low at $2.0 million in Q2 2026.
• Average Non Operating Interest Expenses over 3 years is $9.6 million, with a median of $10.0 million recorded in 2024.
• The sharpest annual moves came in 2025 and 2026: Non Operating Interest Expenses soared 66.67% in 2025, then plunged 86.67% in 2026.
• Over 3 years, Non Operating Interest Expenses stood at $13.0 million in 2024, then tumbled by 53.85% to $6.0 million in 2025, then slumped by 66.67% to $2.0 million in 2026.
• The last three Non Operating Interest Expenses figures came in at $2.0 million (Q2 2026), $7.0 million (Q1 2026), and $6.0 million (Q4 2025), per Business Quant data.